Basic Information
| LncRNA/CircRNA Name | DLEU2 |
| Synonyms | DLEU1, BCMS, BCMS1, DLB1, DLEU2, LEU1, LEU2, LINC00021, NCRNA00021, XTP3 |
| Region | GRCh38_13:49982552-50125720 |
| Ensemble | ENSG00000231607 |
| Refseq | NR_002612 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown, etc. |
| Sample | glioma tissues, normal astrocyte (NHA) cell line,glioma cell lines (U87, U251, U343) |
| Expression Pattern | up-regulated |
| Function Description | First, we found that lncRNA-DLEU2 is highly expressed in glioma tissues and cell lines. Next, experiments in cells showed that lncRNA-DLEU2 knockdown inhibited, whereas lncRNA-DLEU2 overexpression promoted, the clone formation, migration and invasion of glioma cells. A luciferase reporter assay and an RNA immunoprecipitation assay demonstrated that lncRNA-DLEU2 acts as a sponge for miR-186-5p in glioma cells. Further, studies suggested that miR-186-5p inhibits the expression of PDK3, which is an oncogene in glioma. Moreover, with rescue experiments, we demonstrated that lncRNA-DLEU2 regulates the expression of PDK3 and the progression of glioma in a miR-186-5p-dependent manner. Finally, we also showed that lncRNA-DLEU2 promotes glioma growth in a manner that is related to miR-186-5p and PDK3 in vivo. |
| Pubmed ID | 31497209 |
| Year | 2019 |
| Title | The lncRNA-DLEU2/miR-186-5p/PDK3 axis promotes the progress of glioma cells |
External Links
| Links for DLEU2 | GenBank HGNC NONCODE |
| Links for glioma | OMIM COSMIC |